

NHSBT Finance Report

February 2022


Contents	Page
Financial Performance Headlines	2-3
NHSBT – Summary I&E Statement	4
Divisional I&E statements	5-8
Cash & Debtors	9
Contribution Report	10

2021/22 NHSBT Financial Performance Headlines - February 2022

Year to Date deficit of £8.1m (£12.9m ahead of plan)


The full year result for 2021/22 is likely to be significantly better than the forecast at Q3

Blood and Group Net Income & Expenditure (excl. Change Programme)




Significant overspends in Blood Supply partly offset by underspends in Group Services - detail on page 5 & 6

Clinical Services Net Income & Expenditure (Business unit contribution)




£5.7m favourable variance – activity higher than (conservative) plan across most Business Units – detail on page 7

Organ Donation & Transplantation Net Funding & Expenditure




£5.7m favourable variance due to lower activity expenditure and transformation spend – detail on page 8
Additional £1.2m favourable variance reported in TES

Blood and Group Change Programme Full Year Forecast




The transformation forecast now assumes that £4.4m for Blood Tech Modernisation (BTM) can be capitalised.

NHSBT Cash Flow 2021/22



Forecast cash at end March 2022 has increased to £64.5m. (including capitalisation of BTM)

NHSBT I&E Full Year Forecast



At Q3, the full year forecast was a deficit of £15.1m. Including BTM the outturn is now likely to be an £7m-8m deficit.

2021/22 NHSBT Financial Performance Headlines – February 2022

Surpluses in Clinical Services and OTDT more than offsetting overspends in Blood Supply

Year to date I&E Position	£8.1m deficit vs £18.8m budget deficit	Blood/Group	+£0.3m	Significant overspends in Blood Supply (£5.1m) offset by positive variances in group services and lower transformation spend. Detail on pages 5 & 6.	
		Clinical Services	+ £5.7m	Increased activity (income) versus a conservative budget.	
		OTDT	+ £6.9m	ODT (+£5.7m) - activity levels and associated costs lower than plan, plus low transformation spend. TES (+£1.2m) - increased sales income versus a conservative budget.	
Full year forecast	£15.1m deficit vs £23.0m budget deficit	Blood/Group	- £5.0m	Combination of full year effect of adverse expenditure in Blood Supply and a decline in red cell stock (fixed cost movement in stock).	
		Clinical Services	+ £4.7m	Activity higher than conservative plan (especially Stem Cells, RCI and TAS).	
		OTDT	+ £8.2m	ODT (+£7.0m) - activity levels lower than plan plus an additional budgeted NORS team <i>not</i> mobilised. TES (+£1.2m) - full year effect of higher sales income versus a conservative plan.	
Cash and Debtors	Cash balance £62m	Debtor Days		25 days - 3 days behind target	
		90+ day overdues		£0.4m (below the £0.5m - £1.0m target range).	
		Cash		Latest forecast cash at end March 2022 is £64.5m	

A significant improvement on the full year forecast made at Q3 (a £15.1m deficit) is now likely to be seen. This will result from the proposed capitalisation of the Blood Technology Modernisation (BTM) project (£4.4m) along with other emerging underspends. The full year result is now expected to come in at a deficit of around £7m-£8m, around £15m better than plan. As a result we expect NHSBT to end the year with £64.5m cash reserves, with £18m attributable to Blood/Group. Capitalisation of the BTM expenditure is, however, subject to audit and acceptance by DHSC.

Capital - The latest forecast for capital is £7.6m (excluding BTM) versus a £21m budget. Including capitalisation of BTM the full year forecast would be a spend of £12m. The YTD spend at the end of February is £5.3m

Plasma Funding – DHSC has agreed that the 2021/22 project funding can be drawn down in full this year, with any cash not utilised in year carried over to 2022/23. Of the £64.5m forecast cash position at end March 2022, £21.8m is attributable to plasma.


NHSBT Summary I&E statement - February 2022

Period (£k)			Blood and Group	WTE		Year to Date (£k)			Full Year (£k)			
Budget	Actual	Variance		Budget	Actual	Budget	Actual	Variance	Prev. Yr Actual	Budget	Q3 Forecast	Variance
4,100	1,331	(2,769)	Programme Funding - Plasma			35,719	27,503	(8,216)	57,623	46,044	30,803	(15,241)
908	1,023	114	Programme Funding - Corporate			9,992	10,581	590	11,061	10,900	11,996	1,096
24,245	24,350	105	Blood Supply Income			270,242	271,192	950	283,442	295,060	294,555	(505)
407	267	(141)	Group Services Income			4,514	4,897	383	6,616	5,071	5,554	483
29,661	26,971	(2,690)	Blood and Group Income			320,467	314,174	(6,293)	358,742	357,075	342,908	(14,166)
(4,100)	(1,331)	2,769	Plasma for Medicine	313	78	(35,741)	(27,503)	8,238	(57,623)	(46,066)	(29,904)	16,162
45	(52)	(97)	Blood Supply Cost of Sales	0	0	(780)	(2,137)	(1,356)	(515)	0	(1,281)	(1,281)
(12,877)	(13,461)	(584)	Blood Supply Operations	2,515	2,546	(143,618)	(148,887)	(5,269)	(150,304)	(156,792)	(162,595)	(5,803)
(14,226)	(14,546)	(320)	Group Services	1,147	1,069	(155,579)	(152,834)	2,745	(177,269)	(171,327)	(171,224)	103
(1,515)	(1,613)	(98)	Change Programme	12	29	(15,483)	(13,296)	2,187	(12,701)	(16,999)	(16,999)	(0)
(32,674)	(31,004)	(1,161)	Blood and Group Expenditure	3,987	3,722	(351,200)	(344,656)	6,544	(398,412)	(391,183)	(382,002)	9,181
(3,013)	(4,033)	(3,851)	Blood and Group Total	3,987	3,722	(30,734)	(30,482)	251	(39,670)	(34,108)	(39,094)	(4,986)
			Clinical Services (DTAS)									
347	347	0	Programme Funding			3,815	3,815	0	4,173	4,162	4,162	0
5,249	5,939	690	Diagnostic and Therapeutic Services Income			58,998	61,839	2,840	58,602	66,747	68,943	2,196
5,596	6,286	690	Clinical Services Income			62,813	65,654	2,840	62,774	70,909	73,105	2,196
(4,894)	(4,994)	(99)	Diagnostics, Therapeutic Apheresis and Stem Cells Operations	763	727	(54,777)	(54,290)	487	(53,520)	(60,780)	(60,261)	519
(340)	(109)	231	Diagnostics, Therapeutic Apheresis and Stem Cells Change Programme	0	2	(3,400)	(1,007)	2,393	(903)	(3,740)	(1,766)	1,974
(5,234)	(5,103)	131	Clinical Services Expenditure	763	729	(58,177)	(55,297)	2,880	(54,423)	(64,520)	(62,027)	2,493
362	1,183	821	Clinical Services Total	763	729	4,637	10,357	5,720	8,351	6,389	11,078	4,689
			Organ Donation & Transplantation									
6,792	6,748	(44)	Programme Funding (DHSC and Other UK Health Authorities)			74,714	74,575	(139)	74,880	81,506	80,968	(538)
0	0	0	Programme Funding - Opt Out			0	0	0	11,509	0	0	0
278	186	(92)	NHSE Funding			3,056	1,628	(1,428)	1,617	3,333	2,167	(1,166)
7,070	6,934	(135)	ODT Income			77,770	76,202	(1,567)	88,006	84,839	83,135	(1,704)
(5,497)	(5,321)	176	Organ Donation and Transplantation Operations	470	450	(60,739)	(58,020)	2,719	(55,260)	(66,350)	(62,774)	3,576
(1,349)	(1,225)	123	Organ Donation and Transplantation Change Programme	23	33	(13,339)	(8,750)	4,589	(14,860)	(15,302)	(10,174)	5,128
(6,845)	(6,546)	299	ODT Expenditure	493	484	(74,078)	(66,770)	7,308	(70,120)	(81,652)	(72,948)	8,704
225	388	164	ODT Total	493	484	3,692	9,432	5,740	17,886	3,188	10,188	7,000
			Tissues and Eye Services									
1,241	1,082	(159)	Tissue & Eye Services Income			13,020	13,754	734	11,994	14,298	15,238	940
1,241	1,082	(159)	TES Income			13,020	13,754	734	11,994	14,298	15,238	940
(1,053)	(953)	100	Tissue and Eye Services Operations	148	131	(11,631)	(11,201)	429	(11,577)	(12,717)	(12,467)	250
(1,053)	(953)	100	TES Expenditure	148	131	(11,631)	(11,201)	429	(11,577)	(12,717)	(12,467)	250
188	129	(59)	TES Total	148	131	1,389	2,552	1,163	417	1,580	2,770	1,190
			NHSBT Summary									
43,568	41,273	(2,295)	Income			474,070	469,784	(4,286)	521,516	527,121	514,386	(12,734)
(45,806)	(43,607)	2,200	Expenditure	5,392	5,066	(495,086)	(477,925)	17,161	(534,532)	(550,072)	(529,444)	20,628
(2,239)	(2,334)	(95)	NHSBT Surplus/(Deficit)	5,392	5,066	(21,016)	(8,141)	12,875	(13,016)	(22,951)	(15,058)	7,893

Blood and Group - February 2022

Blood Supply	WTE		Year to Date			Full Year		
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Q3 Fcst.	Var.
Blood and Component Income			264.3	264.6	0.3	288.3	288.3	(0.0)
NCI Income			3.1	3.4	0.2	3.4	2.5	(0.9)
Logistics Income			2.8	3.0	0.2	3.3	3.5	0.2
Blood Donation Income			0.0	0.2	0.2	0.0	0.2	0.2
Total Income			270.2	271.2	0.9	295.1	294.6	(0.5)
Cost of Sales - Blood Component Stock Movement			(0.8)	(2.1)	(1.4)	0.0	(1.3)	(1.3)
Blood Donation	1,458	1,469	(65.6)	(69.4)	(3.8)	(71.4)	(75.7)	(4.3)
Manufacturing, Testing & Issue	754	769	(60.0)	(59.9)	0.1	(65.7)	(65.5)	0.1
Logistics	303	308	(18.0)	(19.6)	(1.5)	(19.7)	(21.3)	(1.7)
Total Expenditure	2,515	2,546	(144.4)	(151.0)	(6.6)	(156.8)	(163.9)	(7.1)
Blood Supply Operating Surplus/(Deficit)	2,828	2,624	125.8	120.2	(5.7)	138.2	131.6	(6.7)
Group Services (incl. Change Programme)	1,159	1,098	(156.6)	(150.7)	5.9	(172.4)	(170.7)	1.7
Blood and Group Surplus/(Deficit)	3,987	3,722	(30.7)	(30.5)	0.3	(34.1)	(39.1)	(5.0)

Plasma for Medicine	WTE		Year to Date			Full Year		
(£)m	Bud.	Act.	Bud.	Act.	Var.	Bud.	Q3 Fcst.	Var.
Programme Funding			35.7	27.5	(8.2)	46.0	30.8	(15.2)
Expenditure	313	78	(35.7)	(27.5)	8.2	(46.1)	(29.9)	16.2
Programme Surplus/(Deficit)	313	78	(0.0)	0.0	0.0	(0.0)	0.9	0.9



Group Services detail on page 6

At month 11, Blood and Group Services are reporting an £0.3m favourable variance against plan. This continues to reflect large overspends in Blood Donation and Logistics offset by positive variances in Group and Transformation (see page 6 for detail).

The adverse variance in Blood Supply is driven by continued adverse pay costs in blood collection, as a result of overtime and temporary labour in support of improving collection performance and stabilising red cell stock levels. This is increased further by delayed LRP benefits reported in Logistics combined with rising fuel and courier costs.

The cost pressures in Blood Supply are partially offset by a (£1.3m) Covid contingency reported in Group Services, increased Logistics and BD income (£0.4m) and better than plan contribution in TES of £1.2m (i.e a lower cross subsidy). The income forecast for blood components is in line with plan reflecting the latest demand planning assumptions. Latest forecasts now expect NCI income to finish in line with plan and as a result, does not require Plasma funding to cover any shortfall.

The forecast also assumes an adverse (non-cash) variance for cost of sales of £1.3m. This is based on a forecast red cell stock of 32k units at March 2022, versus actual opening stock of 42.5k units at the start of April 2021.

Group Services - February 2022

Group Services (£)m	WTE		Year to Date			Full Year		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Q3 Fcst.	Var.
Programme Funding			10.0	10.6	0.6	10.9	12.0	1.1
Group Services Income			1.5	2.0	0.5	1.7	2.0	0.3
Medical			1.0	0.9	(0.1)	1.0	1.0	(0.0)
Research & Development			2.1	2.0	(0.0)	2.4	2.6	0.2
Total Income			14.5	15.5	1.0	16.0	17.5	1.6
Chief Executive and Board	4	5	(0.7)	(0.6)	0.1	(0.8)	(0.7)	0.1
Donor Experience	157	134	(18.6)	(18.2)	0.4	(20.5)	(20.5)	0.0
Quality	112	114	(6.6)	(6.5)	0.1	(7.2)	(7.3)	(0.1)
Estates & Facilities	79	71	(40.9)	(40.3)	0.5	(44.8)	(44.8)	(0.0)
Finance	108	98	(6.1)	(6.5)	(0.5)	(6.6)	(7.3)	(0.6)
Strategy and Transformation	46	35	(2.7)	(2.8)	0.0	(2.9)	(3.1)	(0.2)
People	144	142	(9.3)	(10.4)	(1.1)	(10.1)	(11.2)	(1.1)
Digital, Data and Technology Services	266	256	(36.9)	(35.5)	1.4	(40.4)	(40.6)	(0.1)
Research & Development	39	35	(4.3)	(4.2)	0.2	(5.3)	(5.5)	(0.2)
Medical	192	180	(15.7)	(14.9)	0.8	(17.0)	(16.4)	0.6
Miscellaneous and Capital Charges	0	0	(13.9)	(12.9)	1.0	(15.6)	(13.9)	1.7
Total Expenditure	1,147	1,069	(155.6)	(152.8)	2.7	(171.3)	(171.2)	0.1
Operating Surplus/(Deficit)	1,147	1,069	(141.1)	(137.4)	3.7	(155.4)	(153.7)	1.7
Change Programme	12	29	(15.5)	(13.3)	2.2	(17.0)	(17.0)	(0.0)
Group Services Surplus/(Deficit)	1,159	1,098	(156.6)	(150.7)	5.9	(172.4)	(170.7)	1.7

Group Services are reporting a £5.9m year to date positive variance against plan, predominately driven by lower than budget expenditure in Estates, Donor Experience and DDTS. Both Donor Experience and Estates expect to be in line with budget/forecast by year end due to delayed spend (eg media) and phasing of projects (in Estates).

The large adverse cost variance reported against the People directorate is driven by the new operating model and additional resource to aid increased transactional volumes. Likewise, Finance are also reporting higher cost trends against budget, driven by a combination of additional EU Exit costs (fully offset against agreed DHSC programme funding) and additional payroll resource to support significantly increased transaction volumes (collection, plasma, Flowers case, selling leave etc).

Significant upside to the year end forecast made at Q3 is now expected. This is driven by the proposed capitalisation of Blood Tech Modernisation expenditure (£4.4m), hardware underspends in DDTS (£1.0m) and delays in other transformation projects (£1.3m).

Note that a £1.3m unallocated Covid contingency is reported within the Miscellaneous forecast. This is currently being utilised to partially offset the increased cost base reported in Blood Supply and, as a result, the underlying Group Services forecast outturn is broadly in line with budget.


Clinical Services - February 2022 (operating contributions - pre ABC analysis)

(£)m	WTE		Year to Date			Full Year		
	Bud.	Per Act.	Bud.	Act.	Var.	Bud.	Q3 Fcst.	Var.
Therapeutic Apheresis Services								
Income			10.2	11.7	1.5	11.3	13.0	1.7
Expenditure	93	93	(8.1)	(8.1)	0.0	(8.9)	(8.8)	0.1
TAS I&E	93	93	2.0	3.6	1.6	2.3	4.1	1.8
Histocompatibility & Immunogenetics								
Income			12.6	12.6	0.0	13.9	13.6	(0.3)
Expenditure	179	177	(14.4)	(14.5)	(0.2)	(15.7)	(16.0)	(0.3)
H&I I&E	179	177	(1.8)	(1.9)	(0.1)	(1.9)	(2.5)	(0.6)
Red Cell Immunohematology								
Income			17.0	17.3	0.3	18.6	18.9	0.2
Expenditure	193	182	(11.7)	(11.3)	0.4	(12.7)	(12.5)	0.2
RCI I&E	193	182	5.3	6.0	0.6	5.9	6.4	0.5
IBGRL								
Income			2.2	2.1	(0.1)	2.4	2.3	(0.1)
Expenditure	50	46	(3.0)	(3.0)	0.0	(3.3)	(3.3)	0.1
IBGRL I&E	50	46	(0.8)	(0.9)	(0.0)	(0.9)	(0.9)	(0.0)
SCI - Cellular & Molecular Therapies								
Income			10.9	11.2	0.3	12.8	12.8	0.1
Expenditure	104	96	(8.0)	(8.2)	(0.3)	(9.2)	(9.1)	0.1
CMT I&E	104	96	3.0	3.0	(0.0)	3.6	3.8	0.2
CBC								
Income			2.6	2.3	(0.3)	3.9	3.5	(0.4)
Expenditure	35	32	(2.6)	(2.7)	(0.1)	(3.3)	(3.1)	0.1
CBC I&E	35	32	(0.0)	(0.4)	(0.4)	0.7	0.3	(0.3)
SCI - Donation & Transplantation								
Income			7.3	8.4	1.1	8.0	9.1	1.1
Expenditure	46	42	(2.9)	(2.9)	0.0	(3.2)	(3.3)	(0.1)
SCDT I&E	46	42	4.3	5.4	1.1	4.8	5.8	1.0
Transfusion (Excl. R&D and Medical)	21	25	(0.6)	(0.4)	0.2	(0.6)	(0.7)	(0.1)
DTS Management	43	36	(3.5)	(3.0)	0.4	(3.8)	(3.4)	0.4
Operating Surplus/(Deficit)	763	727	8.0	11.4	3.4	10.1	12.8	2.7
Change Programme	0	2	(3.4)	(1.0)	2.4	(3.7)	(1.8)	2.0
Clinical Services Surplus/(Deficit)	763	729	4.6	10.4	5.8	6.4	11.1	4.7

Clinical Services is reporting a £5.8m positive variance at direct contribution level in the year to date results. The latest forecast at M11 however, anticipates that the full year outturn will fall to £5.5m ahead of plan, with forecasts reflecting lower CBC income in M12.

Summary by Business Unit;

- **TAS** favourable income variance driven primarily by ECP. The Q3 forecast suggests a continuation of strong activity performance in Plasma Exchange combined with the assumption that the sustainability allowance will be available for the remainder of the year.
- **H&I** behind plan driven by lower activity driven by a shortfall on service income – specifically Stem Cell related investigations and Solid Organ Routine Antibody testing.
- **RCI** activity above plan predominately driven by a the strong reference activity performance in Q1. The positive variance is increased further by underspends on Pay, driven by a large amount of unfilled vacancies.
- **IBGRL** in line with plan
- **CMT** broadly in line with budget
- **CBC** latest forecast is now anticipating a full year outturn of (-£0.7m), driven by a combination of re-phased project milestones for Lifearc (re-phased into 2022/23, therefore no implications on the project plan), and reduced service income.
- **Stem Cell Donation & Transplantation** favourable against plan primary driven by increased BBMR harvest activity.



Note: Excludes Medical and R&D funding.

ODT - February 2022

ODT I&E (£)m	WTE		Year to Date			Full Year		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Q3 Fcst.	Var.
Programme Funding			62.9	62.9	0.0	68.6	68.6	0.0
Other UK Health Authorities Funding			11.2	11.4	0.2	12.2	12.1	(0.1)
Operating Expenditure	470	450	(60.7)	(58.0)	2.7	(66.3)	(62.8)	3.6
Operating Funding & Expenditure	470	450	13.4	16.3	2.9	14.5	17.9	3.4
Transformation	23	33	(9.7)	(6.9)	2.8	(11.3)	(7.7)	3.6

ODT Surplus/(Deficit)	493	484	3.7	9.4	5.7	3.2	10.2	7.0
Direct contribution to Group Services						(10.8)	(10.8)	0.0
ODT Deficit (funded by cash)						(7.6)	(0.6)	7.0

ODT Transformation Detail	WTE		Year to Date			Full Year		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Q3 Fcst.	Var.
DCD Hearts								
NHSE Funding			0.8	0.8	0.0	0.8	0.8	0.0
Expenditure	1	0	(2.5)	(2.9)	(0.4)	(2.5)	(2.9)	(0.4)
Total	1	0	(1.7)	(2.1)	(0.4)	(1.7)	(2.1)	(0.4)
Donor Characterisation								
NHSE Funding			2.3	0.9	(1.4)	2.5	1.3	(1.2)
Expenditure	3	5	(2.3)	(0.9)	1.4	(2.5)	(1.3)	1.2
Total	3	5	0.0	0.0	(0.0)	0.0	0.0	0.0
Opt Out								
Scotland Funding			0.6	0.3	(0.3)	0.7	0.3	(0.4)
Expenditure	19	15	(2.7)	(2.6)	0.1	(3.2)	(2.8)	0.4
Total	19	15	(2.1)	(2.3)	(0.2)	(2.5)	(2.5)	0.0
ODT Development Fund	0	13	(5.9)	(2.4)	3.5	(7.2)	(3.2)	4.0
Transformation Total	23	33	(9.7)	(6.9)	2.8	(11.3)	(7.7)	3.6

ODT is reporting a £5.7m positive variance at direct operating level in the year to date. This results from lower donation and transplant volumes versus plan (and hence related lower activity costs) versus fixed programme funding, plus lower transformation spend than plan.


The Q3 forecast for the year is based on 1,374 deceased donors versus a plan of 1,697. The related reduction in costs results in an a positive variance of £3.6m for year.

In addition an additional NORS team that was assumed in the budget (included in the ODT Development Fund budget line budget) will not now happen, generating a positive variance of £2.2m.

Transformation spend is also forecast to be £1.4m lower than plan, now that business cases and associated plans, have now been worked up.

Taken together, this results in a total forecast positive contribution variance of £7.0m.

The surplus cash generated by this variance is reflected in NHSBT cash flow forecast. Discussions with DHSC will take place towards the year end, when the surplus cash will either be returned or carried forward against 2022/23 funding requirements (the latter is anticipated).



Tissue and Eye Services – February 2022

TES is reporting a year to date £1.2m positive variance against plan at direct contribution level (ie pre ABC cost allocation). As with Clinical Services this reflects the conservative income level that were set in the budget. TES reported strong recovery over the first half of the year, however, activity has reduced over the second half of the year. This reduced run rate has been reflected in the latest reforecast, which now anticipates a full year favourable outturn of £1.2m.

TES I&E (£)m
Income
Cost of Sales
Expenditure
Surplus/(Deficit)

WTE	
Bud.	Per Act.
148	131
148	131

Year to Date		
Bud.	Act.	Var.
13.0	13.8	0.7
(0.7)	(0.7)	0.0
(10.9)	(10.5)	0.4
1.4	2.6	1.2

Full Year		
Bud.	Q3 Fcst.	Var.
14.3	15.2	0.9
(0.8)	(0.7)	0.1
(12.0)	(11.8)	0.2
1.6	2.8	1.2

Cash Flow – as at February 2022

	Actual Apr-21 £k	Actual May-21 £k	Actual Jun-21 £k	Actual Jul-21 £k	Actual Aug-21 £k	Actual Sep-21 £k	Actual Oct-21 £k	Actual Nov-21 £k	Actual Dec-21 £k	Actual Jan-22 £k	Actual Feb-22 £k	Forecast Mar-22 £k	Total £k
Opening bank balance	53,211	49,942	44,169	32,800	61,342	70,557	63,531	64,245	62,805	57,441	61,582	62,370	53,211
Receipts													
Debtors & Other Receipts	33,878	35,028	37,837	35,339	42,097	30,109	41,722	34,937	32,061	36,309	38,207	42,556	440,079
Revenue Cash Limit	0	0	0	24,158	5,958	5,958	5,958	7,044	5,958	5,958	5,958	7,299	74,251
Revenue Cash Limit - Pensions Uplift	824	0	0	3,633	906	906	906	906	906	906	906	925	11,724
Revenue Cash Limit - Plasma for Medicine	0	0	0	9,090	2,465	0	2,965	0	6,168	0	10,770	21,542	53,000
Capital Cash Limit	0	0	0	0	0	0	8,000	0	0	0	0	4,000	12,000
Total Receipts	34,702	35,028	37,837	72,220	51,426	36,973	59,551	42,887	45,093	43,174	55,841	76,322	591,054
Payments													
Staff Expenses	15,253	20,370	20,881	17,657	20,983	23,376	24,681	20,786	21,574	21,865	20,582	27,530	255,539
Other Revenue Payments	22,286	19,669	27,681	25,403	20,739	20,231	23,510	23,091	28,579	17,111	23,626	39,935	291,859
Capital Charges Less DH Credit Due	0	0	0	0	0	0	10,184	0	0	0	10,184	0	20,367
Capital Payments	432	762	644	618	488	392	462	451	305	57	663	6,725	12,000
Total Payments	37,971	40,801	49,205	43,679	42,210	43,999	58,837	44,328	50,457	39,032	55,055	74,190	579,765
Closing bank balance	49,942	44,169	32,800	61,342	70,557	63,531	64,245	62,805	57,441	61,582	62,370	64,500	64,500

Debtor Days (Target is 22 days)	16	17	14	17	19	18	14	17	13	29	25	
YTD BPPC By Value % (Target is 95%)	92.2%	95.1%	93.5%	94.0%	94.1%	93.6%	94.1%	93.9%	93.4%	92.9%	92.6%	
YTD BPPC By Number % (Target is 95%)	94.3%	97.0%	96.1%	95.7%	95.1%	94.7%	94.7%	94.5%	94.5%	94.3%	94.3%	

Overdue Debtors NBS/ODT £000's	1-30 Days overdue £000's	31-60 Days overdue £000's	61-90 Days overdue £000's	>90 Days overdue £000's	Total Overdue £000's
Total Overdue Debtors	5,062	1,216	336	446	7,060

Top 5 > 90 days Overdue Debtors £000's	Jan-22		Feb-22	
	>90 Days overdue £000's	Total Overdue £000's	>90 Days overdue £000's	Total Overdue £000's
GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS	26	68	40	121
IMPERIAL COLLEGE HEALTHCARE NHS TRUST	36	561	37	1,188
HOMERTON UNIVERSITY HOSPITAL NHS FOUNDATION TRUST			32	105
LIVERPOOL UNIVERSITY HOSPITALS NHS FOUNDATION TRUST			29	391
BARTS HEALTH NHS TRUST	29	59	19	196
UNIVERSITY COLLEGE LONDON	34	38		
LEEDS TEACHING HOSPITALS NHS TRUST	28	206		
Total 5 Overdue Debtors	153	932	157	2,001
Other Debtors	225	4,186	289	5,059
Total Overdue Debtors	379	5,117	446	7,060

Notional Split	£m
Blood	18.8
Clinical Services	10.2
ODT	13.7
Plasma	21.8
NHSBT Total	64.5

>90 DAYS OVERDUE	Profile by Month													
	Actual Apr-21 £000s	Actual May-21 £000s	Actual Jun-21 £000s	Actual Jul-21 £000s	Actual Aug-21 £000s	Actual Sep-21 £000s	Actual Oct-21 £000s	Actual Nov-21 £000s	Actual Dec-21 £000s	Actual Jan-22 £000s	Actual Feb-22 £000s	Actual Mar-22 £000s		
Target Range Between £0.5m and £1.0m														
Ledger Balance at month end	369	467	497	775	648	492	407	436	486	379	446			

Contribution Statement– as at February 2022

Post allocation of costs via the ABC model

Year to date Actual £m	Blood & Components inc. R&D	Diagnostics		Stem Cells			TAS	TES	ODT	NHSBT
		RCI	H&I	CMT	CBC	SCDT				
Income/Funding										
Prices	270.6	18.6	12.0	10.3	0.0	4.5	11.3	13.7	0.0	341.1
Central Funding from DHAs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.2	11.2
Grant in Aid (DHSC Funding)	34.1	0.4	0.3	0.3	0.1	4.0	0.2	0.4	65.4	105.0
Other	5.5	0.8	0.6	0.9	2.3	0.0	0.4	0.0	1.9	12.4
Total Income/Funding	310.2	19.8	12.9	11.5	2.4	8.5	11.9	14.1	78.4	469.8
Expenditure										
Variable Costs	(31.2)	(1.6)	(3.5)	(1.9)	(0.9)	(0.8)	(3.1)	(2.3)	(3.0)	(48.2)
Variable Contribution	279.0	18.2	9.4	9.6	1.5	7.8	8.9	11.9	75.4	421.6
Direct Costs	(145.2)	(9.2)	(6.9)	(6.1)	(1.9)	(3.9)	(4.8)	(10.0)	(57.9)	(245.9)
Direct Contribution	133.8	9.0	2.5	3.5	(0.4)	3.9	4.1	1.9	17.5	175.7
Direct Support Costs	(88.6)	(6.0)	(0.7)	(2.8)	(0.6)	(2.0)	(1.2)	(2.9)	(9.1)	(113.9)
Total Allocated Costs	(265.1)	(16.8)	(11.1)	(10.8)	(3.4)	(6.7)	(9.0)	(15.1)	(70.1)	(408.0)
Total Unallocated Costs	(27.7)	(2.2)	(1.4)	(1.3)	(0.4)	(0.8)	(1.1)	(1.8)	(10.2)	(47.0)
Operating Net Surplus / (Deficit)	17.4	0.9	0.4	(0.7)	(1.4)	1.0	1.8	(2.8)	(1.8)	14.8
Transformation	(13.3)	(0.3)	(0.2)	(0.2)	(0.0)	(0.1)	(0.2)	-	(8.8)	(23.0)
Net Surplus / (Deficit) Inc Transformation	4.1	0.6	0.3	(0.8)	(1.5)	0.9	1.6	(2.8)	(10.5)	(8.1)
Budget	4.1	(0.8)	(0.1)	(1.3)	(1.2)	(0.6)	(0.5)	(4.1)	(16.5)	(21.0)
Variance	0.0	1.4	0.4	0.5	(0.2)	1.5	2.1	1.2	6.0	12.9
RAG	G	G	G	G	R	G	G	G	G	G

Blood at "Green" but it results from the favourable group services and change programme position offsetting large adverse variances reported in Blood Supply.

Specialist Services are at "green", primarily as a result of conservative budgets, except for CBC where expected project income is projected to arrive later than plan.

TES is reporting an improved I&E position, but remains in persistent deficit. The budget for 2022/23 implies that TES should be a cash break even (ie before stock reduction) next year.